Novo Nordisk (NOVOB DC) provides update on the Zeus phase 3 trial in people with ASCVD, CKD and inflammation; adverse event rates similar; higher serious infections with ziltivekimab

A biomarker-positive, endpoint-negative cardiovascular outcomes trial follows a familiar pattern in inflammation-targeting drug development: strong hsCRP reduction confirming IL-6 pathway engagement, but no translation into MACE reduction, consistent with prior episodes where surrogate inflammatory markers moved cleanly while hard outcomes did not. A hazard ratio centred on unity with a confidence interval straddling one leaves little room for a favourable subgroup read, and past readouts of this kind have effectively ended the cardiovascular indication rather than prompting re-analysis. The elevated serious infection signal, against otherwise comparable adverse event rates, is the detail regulators and clinicians have historically weighed most heavily when efficacy is absent, and it colours any remaining development path in other indications. The asset sits outside Novo's core metabolic franchise, so precedent suggests read-across to the obesity and diabetes pipeline is limited; the question is rather what this implies for other IL-6 programmes in the same ASCVD, CKD and inflammation population, where peers have pursued similar hypotheses. Worth noting is any formal statement on continuation or termination of the ziltivekimab programme and whether management addresses it on the next scheduled update.